Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members.
She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees.
Overall, she has more than 25 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.
LATEST
Big Pharma and Sustainability: Tracking Companies’ Goals
In 2022, both the EU and the US will continue policy moves to evaluate vulnerabilities in bio/pharma supply chains and recommend solutions to address those vulnerabilities.
What’s Ahead for the Global Bio/Pharma Market in 2022 & Beyond
Investors and capital markets are playing an increasingly important role in CEOs’ decision-making for their companies’ sustainability goals and actions.
Why Governments Need to Invest in Local Pharmaceutical Manufacturing, Research and Development
With much of the world now reliant on China and India for pharmaceuticals and the raw materials needed to make them, the risks of this reliance are now coming into…
Novartis CEO Targets 20 Key Drugs as Potential Blockbusters
Novartis CEO Vasant Narasimhan is banking on six drugs in the near term and 20 pipeline assets longer term as potential blockbusters. What are the key products?
The EU and Medicines Shortages: Root Causes and Mitigation
The European Commission released a new report detailing medicines shortages in the EU, with manufacturing and quality a leading cause. What’s the solution?
Advanced ODT Technologies for Drug Development in Japan and the US
Since its introduction in the 1980s, the market for orally disintegrating tablets (ODTs) has grown annually, and ODTs are now available in a variety of therapeutic areas, both over-the-counter and…
As 2021 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2021? DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made.
AstraZeneca is one of seven companies to have its sustainability plan verified under a new science-based Net-Zero Standard for corporate net-zero emissions target-setting. What’s behind the standard?
